{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T12:37:01Z","timestamp":1788871021363,"version":"build-2803163510"},"reference-count":35,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2013,12,2]],"date-time":"2013-12-02T00:00:00Z","timestamp":1385942400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"crossref","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bjui-journals.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["BJU International"],"published-print":{"date-parts":[[2014,3]]},"abstract":"\n Objective<\/jats:title>\n \n \n \n \n To characterise the incidence, onset, management, predictors, and clinical impact of mammalian target of rapamycin (\n mTOR<\/jats:styled-content>\n ) inhibitor\u2010associated non\u2010infectious pneumonitis (\n NIP<\/jats:styled-content>\n ) on patients with metastatic renal cell carcinoma (\n mRCC<\/jats:styled-content>\n ).\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Patients and Methods<\/jats:title>\n \n \n \n \n Retrospective review of 310 patients with\n mRCC<\/jats:styled-content>\n who received temsirolimus and\/or everolimus between\n J<\/jats:styled-content>\n une 2007 and\n O<\/jats:styled-content>\n ctober 2010.\n <\/jats:p>\n <\/jats:list-item>\n \n Clinical correlations were made with serial radiological imaging.<\/jats:p>\n <\/jats:list-item>\n \n \n Fisher's exact,\n W<\/jats:styled-content>\n ilcoxon rank\u2010sum, and logistic regression analyses were used to evaluate the association of\n NIP<\/jats:styled-content>\n with demographic or clinical factors.\n <\/jats:p>\n <\/jats:list-item>\n \n \n Log\u2010rank and\n C<\/jats:styled-content>\n ox proportional hazards regression analyses were used for the time\u2010to\u2010event analysis.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n \n \n \n NIP<\/jats:styled-content>\n occurred in 6% of temsirolimus\u2010treated and 23% of everolimus\u2010treated patients. Symptoms included cough, dyspnoea, and fever (median of two and three symptoms per patient, respectively).\n <\/jats:p>\n <\/jats:list-item>\n \n The median National Cancer Institute Common Toxicity Criteria for Adverse Events pneumonitis grade was 2 for both groups.<\/jats:p>\n <\/jats:list-item>\n \n \n Older age and everolimus treatment were predictive of\n NIP<\/jats:styled-content>\n .\n <\/jats:p>\n <\/jats:list-item>\n \n \n Patients who developed\n NIP<\/jats:styled-content>\n had a significantly longer time on treatment (median 4.1 vs 2 months) and overall survival (\n OS<\/jats:styled-content>\n ) (median 15.4 vs 7.4 months).\n <\/jats:p>\n <\/jats:list-item>\n \n \n NIP<\/jats:styled-content>\n was a predictor of improved\n OS<\/jats:styled-content>\n by multivariate analysis.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n \n \n \n There was an increased incidence of\n NIP<\/jats:styled-content>\n in everolimus\u2010treated patients.\n <\/jats:p>\n <\/jats:list-item>\n \n \n Improved\n OS<\/jats:styled-content>\n in patients who developed\n NIP<\/jats:styled-content>\n is an intriguing finding and should be further investigated. Given the incidence, morbidity, and outcomes seen in patients on everolimus who develop\n NIP<\/jats:styled-content>\n , management should include proactive monitoring and treatment of\n NIP<\/jats:styled-content>\n with the goal of preserving\n mTOR<\/jats:styled-content>\n inhibitor therapy.\n <\/jats:p>\n <\/jats:list-item>\n <\/jats:list>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/bju.12420","type":"journal-article","created":{"date-parts":[[2013,8,23]],"date-time":"2013-08-23T01:18:56Z","timestamp":1377220736000},"page":"376-382","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":45,"title":["Mammalian target of rapamycin (\n mTOR<\/scp>\n ) inhibitor\u2010associated non\u2010infectious pneumonitis in patients with renal cell cancer: predictors, management, and outcomes"],"prefix":"10.1111","volume":"113","author":[{"given":"Bradley J.","family":"Atkinson","sequence":"first","affiliation":[{"name":"Department of Pharmacy Clinical Programs University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diana H.","family":"Cauley","sequence":"additional","affiliation":[{"name":"Department of Pharmacy Clinical Programs University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chaan","family":"Ng","sequence":"additional","affiliation":[{"name":"Department of Diagnostic Radiology University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randall E.","family":"Millikan","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lianchun","family":"Xiao","sequence":"additional","affiliation":[{"name":"Department of Biostatistics University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Corn","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jonasch","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar M.","family":"Tannir","sequence":"additional","affiliation":[{"name":"Department of Genitourinary Medical Oncology University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2013,12,2]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa066838"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)61039-9"},{"key":"e_1_2_6_4_1","unstructured":"National Comprehensive Cancer Network.NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. V1.2013. Available at:http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/kidney.pdf. Accessed May 2013"},{"key":"e_1_2_6_5_1","unstructured":"European Association of Urology.EAU Guidelines on Renal Cell Carcinoma.2013. Available at:http:\/\/www.uroweb.org\/gls\/pdf\/10_Renal_Cell_Carcinoma_LRV2.pdf. Accessed May 2013"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11523-011-0174-9"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn066"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2010.29.2235"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2006.03.015"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25219"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200911-1720OC"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2012.03.012"},{"key":"e_1_2_6_13_1","unstructured":"National Cancer Institute.Common Terminology Criteria for Adverse Events (CTCAE). Version 4.0. Available at:http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010\u201006\u201014_QuickReference_5x7.pdf. Accessed May 1 2013"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrclinonc.2010.21"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1109653"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds115"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-200109150-00008"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.TP.0000118413.92211.B6"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-2167"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2011-0163"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cct.2008.01.004"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(10)70278-3"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70311-0"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa033025"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2006.08.1620"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24088"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.26.5561"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdm184"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djr128"},{"issue":"9","key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S0923-7534(20)33379-2","article-title":"Clinic and home blood pressure measurements are reliable for guiding therapy in patients with metastatic renal cell carcinoma receiving Axitinib as first\u2010line therapy","volume":"23","author":"Grunwald V","year":"2012","journal-title":"Ann Oncol"},{"issue":"15","key":"e_1_2_6_32_1","doi-asserted-by":"crossref","first-page":"3543","DOI":"10.1200\/jco.2008.26.15_suppl.3543","article-title":"Association of diastolic blood pressure (dBP) >= 90\u2009mmHg with overall survival (OS) in patients treated with axitinib (AG\u2010013736)","volume":"26","author":"Rini BI","year":"2008","journal-title":"J Clin Oncol"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6604497"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.urolonc.2010.07.015"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.25422"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.3701"}],"container-title":["BJU International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbju.12420","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bju.12420","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T18:08:52Z","timestamp":1761761332000},"score":1,"resource":{"primary":{"URL":"https:\/\/bjui-journals.onlinelibrary.wiley.com\/doi\/10.1111\/bju.12420"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,2]]},"references-count":35,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2014,3]]}},"alternative-id":["10.1111\/bju.12420"],"URL":"https:\/\/doi.org\/10.1111\/bju.12420","archive":["Portico"],"relation":{},"ISSN":["1464-4096","1464-410X"],"issn-type":[{"value":"1464-4096","type":"print"},{"value":"1464-410X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,2]]},"assertion":[{"value":"2013-12-02","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}